1 week Ago By Defense World Staff
Prudential Financial Inc. decreased its position in Exact Sciences Co. ( NASDAQ:EXAS – Free Report ) by 46.
1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,089 shares of the medical research company’s stock after selling 6,055 shares during the quarter. Prudential Financial Inc.
’s holdings in Exact Sciences were worth $398,000 as of its most recent SEC filing. Several other institutional investors have also recently added to or reduced their stakes in the business. Captrust Financial Advisors increased its position in Exact Sciences by 24.
5% in the third quarter. Captrust Financial Advisors now owns 9,433 shares of the medical research company’s stock worth $643,000 after buying an additional 1,854 shares during the period. Quantinno Capital Management LP bought a new position in Exact Sciences during the third quarter valued at about $223,000.
Stifel Financial Corp boosted its position in shares of Exact Sciences by 2.3% during the 3rd quarter. Stifel Financial Corp now owns 80,961 shares of the medical research company’s stock valued at $5,515,000 after purchasing an additional 1,825 shares in the last quarter.
Nomura Asset Management Co. Ltd. grew its position in Exact Sciences by 12.
4% in the third quarter. Nomura Asset Management Co. Ltd.
now owns 51,437 shares of the medical research company’s stock worth $3,504,000 after buying an additional 5,664 shares during the last quarter. Finally, M&T Bank Corp grew its holdings in shares of Exact Sciences by 43.5% in the 3rd quarter.
M&T Bank Corp now owns 9,256 shares of the medical research company’s stock worth $630,000 after acquiring an additional 2,806 shares during the last quarter. Institutional investors own 88.82% of the company’s stock.
Wall Street Analyst Weigh In Several research analysts have recently weighed in on EXAS shares. Royal Bank of Canada started coverage on shares of Exact Sciences in a research report on Thursday, March 13th. They issued a “sector perform” rating and a $52.
00 target price on the stock. Piper Sandler cut their price target on Exact Sciences from $75.00 to $70.
00 and set an “overweight” rating for the company in a research note on Wednesday, February 26th. Scotiabank lifted their price objective on shares of Exact Sciences from $70.00 to $73.
00 and gave the company a “sector outperform” rating in a research note on Monday, February 24th. William Blair restated an “outperform” rating on shares of Exact Sciences in a report on Thursday, February 20th. Finally, Guggenheim set a $60.
00 price target on shares of Exact Sciences and gave the company a “buy” rating in a report on Friday, March 28th. Two research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $70.
26. Exact Sciences Trading Up 12.9 % Shares of EXAS stock opened at $45.
50 on Thursday. The company has a quick ratio of 1.93, a current ratio of 2.
15 and a debt-to-equity ratio of 0.97. The company has a market capitalization of $8.
45 billion, a P/E ratio of -8.17 and a beta of 1.14.
Exact Sciences Co. has a 12-month low of $39.97 and a 12-month high of $73.
81. The firm has a 50-day moving average price of $47.38 and a 200 day moving average price of $56.
14. Exact Sciences ( NASDAQ:EXAS – Get Free Report ) last announced its earnings results on Wednesday, February 19th. The medical research company reported ($0.
06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.23.
Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%.
The company had revenue of $713.42 million during the quarter, compared to analyst estimates of $701.45 million.
Research analysts forecast that Exact Sciences Co. will post -0.58 earnings per share for the current fiscal year.
Exact Sciences Profile ( Free Report ) Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
Further Reading Five stocks we like better than Exact Sciences Upcoming IPO Stock Lockup Period, Explained Quantum Computing: The $6.5 Billion Opportunity You Can’t Ignore What is a support level? Are Tariffs Threatening Disney’s Comeback Story? Election Stocks: How Elections Affect the Stock Market Is Alphabet a Generational Buying Opportunity at These Levels? Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter .
.
